Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2A5 VHH CAR-T
- Development stage
- Preclinical
- Lead developer
- Shanghai HRAIN Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
2A5 VHH CAR-T is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target CD70, a member of the tumor necrosis factor (TNF) superfamily that is overexpressed in various cancers, including renal cell carcinoma (RCC), while showing limited expression in healthy tissues. Developed by HRAIN Biotechnology, the therapy incorporates a VHH (variable domain of heavy-chain-only antibody) binder, also known as a nanobody, which is derived from an immunized alpaca library. In preclinical models, 2A5 VHH CAR-T cells demonstrated potent in vitro cytotoxicity and in vivo anti-tumor activity, including significant expansion and cytokine production (IL-2) upon antigen encounter. The use of VHH binders in CAR-T construction is intended to provide high affinity and stability while potentially reducing the risk of immunogenicity compared to traditional scFv-based CARs.
- Other names
- anti-CD70 2A5 VHH CAR-Tanti-CD-70 2A5 VHH CAR-Tanti-CD 70 2A5 VHH CAR-T
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on 2A5 VHH CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2A5 VHH CAR-T.